Trump threatens pharmaceutical tariffs of 200%

President Donald Trump threatened to apply tariffs up to 200% of drugs imported to the United States on Tuesday.

Trump, at a cabinet meeting, “200%will be very high tariffs,” he said.

However, these taxes “people about a year, years and a half,” he said, saying that he would not enter into force immediately.

Tr We will give them a certain time to bring them together, Tr Trump said, apparently referring to the drug producers who brought production back to the USA.

Trade Secretary Howard Lutnick told CNBC to CNBC after the cabinet meeting, and the drug tariffs “will come at the end of the month,” he said.

“With pharmaceuticals and semiconductors, these studies are completed at the end of the month, so the president will then determine his policies and let me wait to decide how to do it.” He said.

The president has repeatedly threatened and then changed the route about tariff offers, so there is no guarantee that it will determine 200% drug tariffs. Pharmaceutical stocks did not change to a great extent after Trump’s comments.

In a note made on Tuesday, Leerink Partners Analyst David Risinger said he believes that the announcement is positive for the sector, because the tariffs will not be applied immediately… And it is unclear whether the management will follow in the future.

It is the most important interpretation of Farmasötike -specific tariffs since April 232 of Trump’s management on these products. This legal authority allows the trade secretary to investigate the impact of imports on national security.

The scheduled tariffs would take a long -awaited blow to pharmaceutical companies with many of them. pushed back And he warned that taxes can increase costs, deterrence investments in the United States and disrupt the supply chain of drugs and risk patients at risk. The industry sprinks Trump’s drug pricing policies, which they claim to threaten both sub -lines and capacity to invest in research and development.

Trump said tariffs will encourage pharmaceutical companies to move production operations to the USA Hand Lilly– Johnson & Johnson– Abbvie And others put more money in the US after domestic drug production has shrunk significantly in the last few decades.

Phrma, the largest lobby group in the US industry, reiterated an previous statement that returned to pharmaceutical tariffs.

“Every dollar spent on tariffs is an unintentional dollar for American manufacturing or the development of future treatments and treatments for patients,” Phrma Public Relations Vice President of the Public Relations. He said.

“The industry shares President Trump’s goal of reviving American manufacturing, and recently announced hundreds of billions of dollars in US investments, but putting tariffs on drugs will be inefficient against these efforts.” “Drugs are historically exempted from tariffs because they can increase costs and lead to famine.”